TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 62.8nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 67.8nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 202nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 239nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
Affinity DataIC50: 304nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 418nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 418nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 422nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 795nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 939nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.62E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90E+3nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.28E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 2.92E+3nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
Affinity DataIC50: 2.94E+3nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.96E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.35E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.68E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.97E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 5.11E+3nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.39E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 5.48E+3nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
Affinity DataIC50: 5.67E+3nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.17E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.25E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.25E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.30E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.73E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 9.32E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.07E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.10E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.62E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.67E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.69E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.73E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.75E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.76E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.96E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.99E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.06E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 2.17E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
Affinity DataIC50: 2.26E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.33E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.41E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 2.45E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
Affinity DataIC50: 2.57E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair
Affinity DataIC50: 2.81E+4nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair